| 1 (126) | Hoffmann-La Roche, GmbH., Germany | DEU |  |
| 2 (134) | Novartis Institutes for Biomedical Research, Switzerland | CHE | |
| 3 (221) | AstraZeneca, United Kingdom | GBR | |
| 4 (233) | Siemens AG, Germany | DEU | |
| 5 (254) | BMJ Group | GBR | |
| 6 (260) | Hoffmann-La Roche Ltd, Switzerland | CHE | |
| 7 (283) | Merck KGaA, Germany | DEU | |
| 8 (309) | GlaxoSmithKline, United Kingdom | GBR | |
| 9 (312) | Novo Nordisk A/S | DNK | |
| 10 (321) | Janssen Research & Development, LLC | BEL | |
| 11 (332) | Boehringer Ingelheim GmbH Germany | DEU | |
| 12 (338) | Bayer AG, Germany | DEU | |
| 13 (392) | Philips Research, Eindhoven | NLD | |
| 14 (406) | Novartis, Switzerland | CHE | |
| 14 (406) | VTT Technical Research Centre of Finland | FIN | |
| 16 (441) | AstraZeneca, Sweden | SWE | |
| 17 (442) | GlaxoSmithKline, Belgium | BEL | |
| 18 (451) | Danone Nederland BV | NLD | |
| 19 (456) | BASF, Germany | DEU | |
| 20 (457) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA | |
| 21 (494) | Nestle Switzerland | CHE | |
| 22 (520) | Pfizer Inc, United Kingdom | GBR | |
| 23 (531) | UCB Pharma SA, Brussels | BEL | |
| 24 (555) | SINTEF Group | NOR | |
| 25 (597) | Eli Lilly and Company Ltd., United Kingdom | GBR | |
| 26 (630) | IMEC International | BEL | |
| 27 (701) | Elsevier, France | FRA | |
|
